• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

48 周长效卡替拉韦和利匹韦林方案治疗的 ATLAS 和 FLAIR 参与者的患者报告结局。

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.

机构信息

Health Analytics and Outcomes Ltd, London, UK.

Hospital Clínico Universitario, Santiago de Compostela, Spain.

出版信息

AIDS Behav. 2020 Dec;24(12):3533-3544. doi: 10.1007/s10461-020-02929-8.

DOI:10.1007/s10461-020-02929-8
PMID:32447500
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7667137/
Abstract

The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability/acceptance (PIN), and treatment preference. In pooled analyses, LA-treated patients (n = 591) demonstrated greater mean improvements from baseline than the CAR group (n = 591) in treatment satisfaction (Week 44, + 3.9 vs. +0.5 HIVTSQs-points; p < 0.001) and acceptance (Week 48, +8.8 vs. +2.0 ACCEPT-points; p < 0.001). The acceptability of injection site reactions (PIN) significantly improved from week 5 (2.10 points) to week 48 (1.62 points; p < 0.001). In both studies, ≥ 97% of LA group participants with recorded data preferred LA treatment compared with prior oral therapy. These results further support the potential of a monthly injectable option for people living with HIV seeking an alternative to daily oral treatment.

摘要

这两项研究（ATLAS 和 FLAIR）均采用患者报告结局（PRO）工具来衡量治疗满意度（HIVTSQ）和接受度（ACCEPT 一般领域）、健康状况（SF-12）、注射耐受性/接受度（PIN）和治疗偏好。在汇总分析中，接受长效（LA）肌内注射卡替拉韦和利匹韦林维持治疗的患者（n=591）与接受当前抗逆转录病毒（CAR）口服治疗的患者（n=591）相比，在治疗满意度（第 44 周，+3.9 比+0.5 HIVTSQ 分；p<0.001）和接受度（第 48 周，+8.8 比+2.0 ACCEPT 分；p<0.001）方面均有更大的平均改善。注射部位反应（PIN）的可接受性从第 5 周（2.10 分）显著改善至第 48 周（1.62 分；p<0.001）。在这两项研究中，≥97%记录数据的 LA 组参与者表示更喜欢 LA 治疗，而不是之前的口服治疗。这些结果进一步支持了每月注射一次的选择对于寻求替代每日口服治疗的 HIV 感染者的潜在应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/61d7e79dd992/10461_2020_2929_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/71439bc8b98c/10461_2020_2929_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/5a41ecea1e09/10461_2020_2929_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/a679e4a491c4/10461_2020_2929_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/10395aa24f87/10461_2020_2929_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/61d7e79dd992/10461_2020_2929_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/71439bc8b98c/10461_2020_2929_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/5a41ecea1e09/10461_2020_2929_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/a679e4a491c4/10461_2020_2929_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/10395aa24f87/10461_2020_2929_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd06/7667137/61d7e79dd992/10461_2020_2929_Fig5_HTML.jpg

相似文献

1
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.48 周长效卡替拉韦和利匹韦林方案治疗的 ATLAS 和 FLAIR 参与者的患者报告结局。
AIDS Behav. 2020 Dec;24(12):3533-3544. doi: 10.1007/s10461-020-02929-8.
2
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).通过评估每 4 或 8 周给药的长效卡替拉韦和利匹韦林的 HIV-1 临床试验，患者报告结果在 1 年内的情况（ATLAS-2M）。
Patient. 2021 Nov;14(6):849-862. doi: 10.1007/s40271-021-00524-0. Epub 2021 May 31.
3
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.患者报告的卡博特韦+利匹韦林长效注射剂治疗HIV-1感染的耐受性和可接受性：随机LATTE-2研究的96周结果
HIV Res Clin Pract. 2019 Aug-Oct;20(4-5):111-122. doi: 10.1080/25787489.2019.1661696. Epub 2019 Sep 18.
4
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.长效肌内注射卡替拉韦和利匹韦林治疗成人 HIV-1 感染（LATTE-2）：一项随机、开放标签、2b 期、非劣效性试验的 96 周结果。
Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.
5
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.长效卡博替拉韦加利匹韦林用于治疗成人 HIV-1 感染：随机、开放标签、3 期 FLAIR 研究的 96 周结果。
Lancet HIV. 2021 Apr;8(4):e185-e196. doi: 10.1016/S2352-3018(20)30340-4.
6
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.在感染 HIV-1 的成人中直接注射或口服先导药物启动长效卡替拉韦/利匹韦林：FLAIR 研究开放标签 3 期第 124 周结果。
Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14.
7
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.长效注射用卡替拉韦+利匹韦林用于 HIV 维持治疗：第 3 阶段 ATLAS 和 FLAIR 试验的第 48 周汇总分析。
J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466.
8
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.长效卡博特韦和利匹韦林用于 HIV-1 感染的口服诱导后。
N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4.
9
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.长效卡替拉韦和利匹韦林每 2 个月给药 1 次用于治疗成人 HIV-1 感染（ATLAS-2M）：96 周结果：一项随机、多中心、开放性标签、3b 期、非劣效性研究。
Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11.
10
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.长效卡博特韦和利匹韦林每 2 个月给药 1 次用于治疗 HIV-1 感染成人（ATLAS-2M）：48 周结果：一项随机、多中心、开放标签、3b 期、非劣效性研究。
Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9.

引用本文的文献

1
Treatment experience of people living with HIV who transitioned from oral to long-acting injectable antiretrovirals in Puerto Rico: A qualitative study.波多黎各从口服抗逆转录病毒药物转换为长效注射用抗逆转录病毒药物的艾滋病毒感染者的治疗经历：一项定性研究。
PLoS One. 2025 Sep 15;20(9):e0332661. doi: 10.1371/journal.pone.0332661. eCollection 2025.
2
The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections.利匹韦林探寻治疗HIV感染神奇药物的曲折之路。
Viruses. 2025 Jul 8;17(7):959. doi: 10.3390/v17070959.
3
Long-Term Real-World Use of Cabotegravir/Rilpivirine: Adherence and Virological Efficacy over a 44-Month Observation Period.

本文引用的文献

1
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.长效卡替拉韦和利匹韦林维持治疗 HIV-1 抑制。
N Engl J Med. 2020 Mar 19;382(12):1112-1123. doi: 10.1056/NEJMoa1904398. Epub 2020 Mar 4.
2
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.长效卡博特韦和利匹韦林用于 HIV-1 感染的口服诱导后。
N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4.
3
Anxiety, depression and treatment adherence among HIV-infected migrants.感染艾滋病毒的移民中的焦虑、抑郁与治疗依从性
卡博特韦/利匹韦林的长期真实世界使用情况：44个月观察期内的依从性和病毒学疗效
Infect Dis Ther. 2025 Jul 8. doi: 10.1007/s40121-025-01178-3.
4
Clinical Outcomes and Perspectives of People With Human Immunodeficiency Virus Type 1 Twelve Months After Initiation of Long-acting Cabotegravir and Rilpivirine in an Observational Real-world US Study (BEYOND).美国一项观察性真实世界研究（BEYOND）中，1型人类免疫缺陷病毒感染者在开始使用长效卡博特韦和利匹韦林十二个月后的临床结局与展望
Open Forum Infect Dis. 2025 Apr 19;12(5):ofaf220. doi: 10.1093/ofid/ofaf220. eCollection 2025 May.
5
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV.一项评估高浓度长效卡博特韦制剂在未感染艾滋病毒成人中的药代动力学、安全性和耐受性的随机1期研究。
Clin Pharmacol Drug Dev. 2025 Jul;14(7):528-541. doi: 10.1002/cpdd.1538. Epub 2025 Apr 29.
6
Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines.根据2021年美国食品药品监督管理局（FDA）指南，长效注射用抗逆转录病毒疗法使用增加对美国艾滋病毒发病率和病毒抑制的影响。
AIDS. 2025 Jul 1;39(8):1024-1031. doi: 10.1097/QAD.0000000000004144. Epub 2025 Feb 4.
7
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.在HIV-1病毒得到抑制的成年患者中进行卡博特韦+利匹韦林大腿注射：3b期ATLAS-2M研究的一项子研究
Clin Infect Dis. 2025 Aug 1;81(1):101-112. doi: 10.1093/cid/ciae620.
8
Qualitative evaluation of survey questions to assess treatment preference for daily oral or long‑acting injectable antiretroviral therapy among people living with HIV.对调查问卷问题的定性评估，以评估艾滋病毒感染者对每日口服或长效注射抗逆转录病毒疗法的治疗偏好。
PLoS One. 2024 Dec 27;19(12):e0309588. doi: 10.1371/journal.pone.0309588. eCollection 2024.
9
Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting.长效抗逆转录病毒疗法的有效性和患者满意度的患者问卷调查：来自真实世界的数据。
BMC Infect Dis. 2024 Sep 16;24(1):979. doi: 10.1186/s12879-024-09904-x.
10
Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.患者参与者对长效卡替拉韦和利匹韦林实施的看法：来自欧洲地点卡替拉韦和利匹韦林实施研究（CARISEL）的研究结果。
J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241269837. doi: 10.1177/23259582241269837.
AIDS Care. 2019 Aug;31(8):979-987. doi: 10.1080/09540121.2019.1601676. Epub 2019 Apr 8.
4
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.奥瑞珠单抗输注在复发型和原发进展型多发性硬化症患者中的应用经验：来自 III 期随机 OPERA I、OPERA II 和 ORATORIO 研究的结果。
Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.
5
Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review.分布和锚定基方法在肿瘤患者报告结局问卷中的最小重要差异的确定：系统评价。
Health Qual Life Outcomes. 2018 Dec 11;16(1):228. doi: 10.1186/s12955-018-1055-z.
6
Interest of Youth Living With HIV in Long-Acting Antiretrovirals.青少年对长效抗逆转录病毒药物的兴趣。
J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):190-197. doi: 10.1097/QAI.0000000000001896.
7
Assessing patients' acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community.评估患者对其用药的接受程度以揭示未满足的需求：一项使用患者在线社区的大型多疾病研究的结果。
Health Qual Life Outcomes. 2018 Jul 6;16(1):134. doi: 10.1186/s12955-018-0962-3.
8
Assessing the reliability of the short form 12 (SF-12) health survey in adults with mental health conditions: a report from the wellness incentive and navigation (WIN) study.评估心理健康成年人中简短 12 项健康调查（SF-12）的可靠性：来自健康激励和导航（WIN）研究的报告。
Health Qual Life Outcomes. 2018 Feb 13;16(1):34. doi: 10.1186/s12955-018-0858-2.
9
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.长效注射用抗逆转录病毒疗法的经验：一项针对参与美国和西班牙卡博特韦+利匹韦林（LATTE-2）II期研究的艾滋病毒感染者的定性研究。
PLoS One. 2018 Jan 5;13(1):e0190487. doi: 10.1371/journal.pone.0190487. eCollection 2018.
10
Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment-Clinical Points of View and Practical Considerations.提高抗逆转录病毒疗法的依从性，这是成功进行HIV治疗的一项艰巨但必不可少的任务——临床观点与实际考量
Front Pharmacol. 2017 Nov 23;8:831. doi: 10.3389/fphar.2017.00831. eCollection 2017.